Publisher
Springer Berlin Heidelberg
Reference17 articles.
1. Burris HA 3rd, Moore MJ, Andersen J, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
2. Pelzer U, Hempel C, Stieler J, et al. (2002) Oxaliplatin (OXA) in combination with high dose 5-FU (24 h)/folinic acid (FA) as salvage therapy in patients with gemzar-refractory advanced pancreatic cancer. Proc Am Soc Clin Oncol 21:A684
3. Oettle H, Pelzer U, Stieler J, et al. (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol [June 1 Suppl] 23:4031
4. Rothenberg ML, Moore MJ, Von Hoff DD, et al. (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347–353
5. Sharma JJ, Razvillas B, Stephens CD, Hilsenbeck SG, Sharma A, Rothenberg ML (1997) Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15:361–364
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献